Gene K Park

US Patent:

D486616, Feb 10, 2004

Filed:

Apr 11, 2001

Appl. No.:

29/140155

Inventors:

Michael J. Hall - South San Francisco CA
James E. Rader - Pleasanton CA
Robert W. Flagler - Pleasanton CA
Scott T. Haubrich - San Leandro CA
Karen S. Hefter - San Ramon CA
Richard Porticos - Los Altos CA
Gene Park - Oakland CA
Douglas Minkler - Livermore CA
David J. Sayler - Portland OR
Eric Y. Park - Portland OR

Assignee:

The Clorox Company - Oakland CA

International Classification:

0401

US Classification:

D32 45

US Patent:

8017140, Sep 13, 2011

Filed:

May 21, 2007

Appl. No.:

11/804997

Inventors:

Syed Faiyaz Ahmed Hossainy - Fremont CA, US
Gordon Stewart - San Francisco CA, US
Deborah Kilpatrick - Los Altos CA, US
Jeffrey Ellis - San Francisco CA, US
Gene Park - Oakland CA, US
Gina Zhang - Fremont CA, US
Paul Consigny - San Jose CA, US
Yiwen Tang - San Jose CA, US

Assignee:

Advanced Cardiovascular System, Inc. - Santa Clara CA

International Classification:

A61F 13/00
A61F 2/00
A61K 9/14

US Classification:

424422, 424423, 424426, 424486

Abstract:

Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

US Patent:

8586069, Nov 19, 2013

Filed:

Dec 29, 2005

Appl. No.:

11/322282

Inventors:

Gordon Stewart - San Francisco CA, US
Gina Zhang - Fremont CA, US
Nancy Kirsten - San Carlos CA, US
Paul Consigny - San Jose CA, US
Stephen Dugan - San Francisco CA, US
Gene Park - Oakland CA, US
Christopher Feezor - San Jose CA, US
Wouter Roorda - Palo Alto CA, US
Syed Faiyaz Ahmed Hossainy - Fremont CA, US

Assignee:

Abbott Cardiovascular Systems Inc. - Santa Clara CA

International Classification:

A61F 13/00
A61F 2/00

US Classification:

424422, 424423

Abstract:

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

US Patent:

20030180083, Sep 25, 2003

Filed:

Jan 24, 2003

Appl. No.:

10/351293

Inventors:

Michael Hall - South San Francisco CA, US
James Rader - Pleasanton CA, US
Boli Zhou - Tualatin OR, US
Karen Hefter - San Ramon CA, US
David Sayler - Portland OR, US
Eric Park - Portland OR, US
Robert Flagler - Pleasanton CA, US
Scott Haubrich - San Leandro CA, US
Shumanta MItra - Dublin CA, US
Richard Porticos - Los Altos CA, US
Gene Park - Pleasanton CA, US

International Classification:

A46B011/00
A47L013/22

US Classification:

401/140000, 401/270000, 401/278000, 401/138000

Abstract:

A cleaning pad for use on a cleaning system in which cleaning fluid or other liquid is dispensed onto a surface in front of a cleaning head portion, the cleaning pad comprising a central absorbent and scrubbing portion, a back edge portion for removably attaching the cleaning pad to the cleaning head portion, and a front edge portion for removably attaching the cleaning pad to the cleaning head portion, the front edge portion having a notch thereon, thereby allowing attachment of the cleaning pad to the cleaning head portion such that cleaning or other fluid can be dispensed from the cleaning head portion onto a surface in front of the cleaning head portion without interference by the cleaning pad.

US Patent:

20050287184, Dec 29, 2005

Filed:

Jun 29, 2004

Appl. No.:

10/881540

Inventors:

Syed Hossainy - Fremont CA, US
Gordon Stewart - San Francisco CA, US
Deborah Kilpatrick - Los Altos CA, US
Jeffrey Ellis - San Francisco CA, US
Gene Park - Oakland CA, US
Gina Zhang - Fremont CA, US
Paul Consigny - San Jose CA, US
Yiwen Tang - San Jose CA, US

International Classification:

A61K031/56
A61K031/4745

US Classification:

424423000, 514171000, 514291000

Abstract:

Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

US Patent:

20060002968, Jan 5, 2006

Filed:

Jun 30, 2004

Appl. No.:

10/882506

Inventors:

Gordon Stewart - San Francisco CA, US
Gina Zhang - Fremont CA, US
Nancy Kristen - San Carlos CA, US
Paul Consigny - San Jose CA, US
Stephen Dugan - San Francisco CA, US
Gene Park - Oakland CA, US
Christopher Feezor - San Jose CA, US
Wouter Roorda - Palo Alto CA, US
Syed Hossainy - Fremont CA, US

International Classification:

A61K 31/4745
A61F 2/00

US Classification:

424423000, 514291000

Abstract:

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.

US Patent:

20080004695, Jan 3, 2008

Filed:

Jun 26, 2007

Appl. No.:

11/768749

Inventors:

Gordon Stewart - San Francisco CA, US
Gina Zhang - Temecula CA, US
Gene Park - Santa Rosa CA, US
Paul Consigny - San Jose CA, US

Assignee:

Abbott Cardiovascular Systems Inc. - Santa Clara CA

International Classification:

A61F 2/82

US Classification:

623001460, 623001420, 424425000

Abstract:

An implantable medical device including a polymer matrix containing everolimus and pimecrolimus, and methods of using the device for the treatment of vascular disease are disclosed.

US Patent:

58799206, Mar 9, 1999

Filed:

Dec 22, 1995

Appl. No.:

8/577894

Inventors:

Douglas A. Dale - Pacifica CA
Alfred L. Gaertner - San Bruno CA
Gene Park - Cincinnati OH
Nathaniel T. Becker - Burlingame CA

Assignee:

Genencor International, Inc. - Rochester NY

International Classification:

C12N 998
C12N 1108
C11D 1000
D06M 1600

US Classification:

435187

Abstract:

A granular enzyme composition is produced having reduced tendency to form dust and leave a residue, and improved stability and delayed release characteristics. The composition has a core, optionally coated with a vinyl polymer, a layer containing an enzyme and a vinyl polymer and optionally a plasticizer or anti-agglomeration agent, and an outer coating containing a polymer and optionally a low residue pigment and/or lubricant. Preferably, the core is a salt or sugar nonpareil, the vinyl polymer coating the core is polyvinyl alcohol and most preferably partially hydrolyzed polyvinyl alcohol, the vinyl polymer in the enzyme layer is polyvinyl pyrrolidone, and the polymer of the outer coating is polyvinyl pyrrolidone, polyvinyl alcohol which may be partially hydrolyzed, polyethylene glycol or mixtures thereof such as a mixture of polyvinyl pyrrolidone and polyvinyl alcohol or a mixture of polyvinyl pyrrolidone and polyethylene glycol. Preferably, the pigment is titanium dioxide and the lubricant is a nonionic or anionic surfactant such as a linear primary alcohol of a 9-15 carbon atom chain length alkane or alkene or an ethoxylate or ethoxysulfate derivative thereof. The enzyme can be a protease, amylase, lipase, cellulase, xylanase, oxidase, peroxidase or mixtures thereof.